Figure 1.
Flow Diagram of Study Patients.
Table 1.
Analysis of the Effect of Rintatolimod on the Primary Endpoint, Exercise Tolerance (ET).
Table 2.
Mean/Median Baseline and Mean/Median Change from Baseline in Exercise Treadmill Duration (seconds) at Week 24 (Stage 2) (ITT Population).
Table 3.
Effect of Rintatolimod (PolyI:C12U) on the Use of Concomitant Medications for the Relief of CFS Symptoms (Stage I).
Table 4.
Secondary Performance Endpoint Improvements in Stage 1.
Table 5.
Safety- Adverse Events (AEs) of Rintatolimod (PolyI:C12U).